Diagnostic Microbiology & Infectious Disease
Volume 66, Issue 2 , Pages 181-186 , February 2010

Effect of oxygen limitation on the in vitro activity of levofloxacin and other antibiotics administered by the aerosol route against Pseudomonas aeruginosa from cystic fibrosis patients

  • Paula King

      Affiliations

    • Mpex Pharmaceuticals, Inc., San Diego, CA 92121-1309, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1-858-875-6672; fax: +1-858-875-2851.
    • ,
  • Diane M. Citron

      Affiliations

    • R. M. Alden Research Laboratory, Culver City, CA 90230, USA
    • ,
  • David C. Griffith

      Affiliations

    • Mpex Pharmaceuticals, Inc., San Diego, CA 92121-1309, USA
    • ,
  • Olga Lomovskaya

      Affiliations

    • Mpex Pharmaceuticals, Inc., San Diego, CA 92121-1309, USA
    • ,
  • Michael N. Dudley

      Affiliations

    • Mpex Pharmaceuticals, Inc., San Diego, CA 92121-1309, USA

Received 19 June 2009 ,Accepted 5 September 2009.

References 

  1. Aaron SD, Ramotar K, Ferris W, Vandemheen K, Saginur R, Tullis E, et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am. J. Respir. Crit. Care. Med. 2004;169:811–815
  2. Borriello G, Richards L, Ehrlich GD, Stewart PS. Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms. Antimicrob. Agents Chemother. 2006;50:382–384
  3. Clinical and Laboratory Standards Institute . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—seventh edition, M7-A7. Wayne, PA: CLSI; 2006;
  4. Cooper MA, Andrews JM, Wise R. Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J. Antimicrob. Chemother. 1991;28:399–405
  5. Cystic Fibrosis Foundation . Patient registry 2006 annual report. 2007;Bethesda, MD: Cystic Fibrosis Foundation
  6. Field TR, White A, Elborn JS, Tunney MM. Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms. Eur. J. Clin. Microbiol. Infect. Dis. 2005;24:677–687
  7. Geller DE, Flume P, Schwab R, Fomos P, Conrad D, Morgan E, et al. A phase I safety, tolerability and pharmacokinetic (PK) study of MP-376 (levofloxacin inhalation solution) in stable cystic fibrosis (CF) patients. Pediatr. Pulmonol. 2008;43(Supp.):S31
  8. Grasemann H, Ioannidis I, Tomkiewicz RP, de Groot H, Rubin BK, Ratjen F. Nitric oxide metabolites in cystic fibrosis lung disease. Arch. Dis. Child. 1998;78:49–53
  9. Hill D, Rose B, Pajkos A, Robinson M, Bye P, Bell S, et al. Antibiotic susceptibilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. J. Clin. Microbiol. 2005;43:5085–5090
  10. Karpati F, Jonasson J. Polymerase chain reaction for the detection of Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia in sputum of patients with cystic fibrosis. Mol. Cell. Probes. 1996;10:397–403
  11. Lewin CS, Morrissey I, Smith JT. The bactericidal activity of sparfloxacin. J. Antimicrob. Chemother. 1992;30:625–632
  12. Lomovskaya O, Lee A, Hoshino K, Ishida H, Mistry A, Warren MS, et al. Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 1999;43:1340–1346
  13. Mesaros N, Nordmann P, Plesiat P, Roussel-Delvallez M, Van Eldere J, Glupczynski Y, et al. Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the new millennium. Clin. Microbiol. Infect. 2007;13:560–578
  14. Morrissey I, Smith JT. Absence of bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions. J. Antimicrob. Chemother. 1992;29:589–590
  15. Palmer KL, Brown SA, Whiteley M. Membrane-bound nitrate reductase is required for anaerobic growth in cystic fibrosis sputum. J. Bacteriol. 2007;189:4449–4455
  16. Saiman L, Siegel J. Infection control in cystic fibrosis. Clin. Microbiol. Rev. 2004;17:57–71
  17. Shawar RM, MacLeod DL, Garber RL, Burns JL, Stapp JR, Clausen CR, et al. Activities of tobramycin and six other antibiotics against Pseudomonas aeruginosa isolates from patients with cystic fibrosis. Antimicrob. Agents Chemother. 1999;43:2877–2880
  18. Valenza G, Tappe D, Turnwald D, Frosch M, Konig C, Hebestreit H, et al. Prevalence and antimicrobial susceptibility of microorganisms isolated from sputa of patients with cystic fibrosis. J. Cyst. Fibros. 2008;7:123–127
  19. Vander Wauven C, Pierard A, Kley-Raymann M, Haas D. Pseudomonas aeruginosa mutants affected in anaerobic growth on arginine: evidence for a four-gene cluster encoding the arginine deiminase pathway. J. Bacteriol. 1984;160:928–934
  20. Worlitzsch D, Tarran R, Ulrich M, Schwab U, Cekici A, Meyer KC, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 2002;109:317–325
  21. Zabinski RA, Walker KJ, Larsson AJ, Moody JA, Kaatz GW, Rotschafer JC. Effect of aerobic and anaerobic environments on antistaphylococcal activities of five fluoroquinolones. Antimicrob. Agents Chemother. 1995;39:507–512
  22. Zumft WG. Cell biology and molecular basis of denitrification. Microbiol. Mol. Biol. Rev. 1997;61:533–616

PII: S0732-8893(09)00374-5

doi: 10.1016/j.diagmicrobio.2009.09.009

Diagnostic Microbiology & Infectious Disease
Volume 66, Issue 2 , Pages 181-186 , February 2010

Article Tools

* Image Usage & Resolution